BMO ARK Genomic Revolution Fund (series A, F, I, Advisor Series and ETF Series units). This Fund invests primarily in global equity securities of companies across various sectors that are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business such as CRISPR, targeted therapeutics, bioinformatics, molecular diagnostics, stem cells and agricultural biology that have the potential for changing the way the world works.